Sheridan, Jan. 09, 2026 (GLOBE NEWSWIRE) -- According to the latest market report published by Wissen Research, the global Car-T Cell Therapy Market was valued at 5.2 billion in 2024. Furthermore, the market is expected to grow at a CAGR of 31 % during the forecast period from 2025 to 2030.
Car-T Cell Therapy Market Report Pricing @ https://www.wissenresearch.com/Pricing/
Car-T Cell Therapy Market Summary
| Car-T Cell Therapy Market Report Attributes | Details |
| Car-T Cell Therapy Market Size (2024) | USD 5.2 Billion |
| Car-T Cell Therapy Market Size (2030) | USD 26.2 Billion |
| CAGR | 31 % |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Key Segments Covered | CAR-T Cell Therapy Market by Product Type. (Breyanzi, Carvykti, Kymriah, Tecartus, Abecma, Yescarta, Others) CAR-T Cell Therapy Market by Disease Type. (Leukaemia, Lymphoma, Multiple Myeloma, Others) CAR-T Cell Therapy Market by Target Antigen. (CD19, BCMA, Others) CAR-T Cell Therapy Market by Patient Type. (Adults, Children’s & Teenagers) CAR-T Cell Therapy Market by End User Type (Hospitals, Specialty Clinics, Others) |
| Regions Covered |
|
US Car-T Cell Therapy Market Size
The US held a majority share in the global car-t cell therapy market and is expected to grow at CAGR of 31.6 % during the forecast period.
Growth Drivers
- Demonstrated high remission rates in certain relapsed/refractory blood cancers validates the therapy.
- Growing understanding of immunology and T-cell biology enables refinement of the technology.
- Unmet medical need in patients with relapsed or refractory cancers drives adoption.
- Advancements in manufacturing processes aim to improve scalability and potentially reduce costs over time.
Opportunities
- Expanding indications into solid tumor represents a major untapped market potential.
- Development of "off-the-shelf" allogeneic CAR T therapies could reduce costs and manufacturing time.
- Combining CAR T-cell therapy with other immunotherapies (like checkpoint inhibitors) could improve efficacy.
- Growing focus on managing and mitigating severe side effects to improve patient outcomes and accessibility.
Key Insights from CAR T-Cell Therapy Market Analysis
CD19 by target antigen dominated the CAR T-Cell therapy market in the year 2024.
CD19 continued to dominate the CAR T-cell therapy market in 2024 due to its proven and high efficacy rates, particularly in treating relapsed or refractory B-cell malignancies like acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), where clinical trials consistently report complete response rates often exceeding 70-90% for ALL and 40-65% for DLBCL. This success solidified CD19 CAR T therapies as the standard of care for these indications, leading to multiple FDA-approved products commanding the vast majority (often >90%) of the overall CAR T market share.
Hospitals held the largest market share by end user type in CAR T-cell therapy market in the year 2024.
Hospitals held the largest market share in the CAR T-cell therapy sector in 2024 due to their indispensable role in managing this complex treatment. CAR T-cell therapy necessitates specialized expertise across multiple disciplines, including oncology, immunology, and critical care, alongside sophisticated infrastructure such as Good Manufacturing Practice (GMP)-compliant facilities for cell processing, advanced laboratories, and intensive care units capable of managing severe potential side effects like cytokine release syndrome.
Asia Pacific is projected to show the highest growth rate in the car-t cell therapy market during the forecast period (2025–2030).
This is driven by a confluence of demographic, economic, and healthcare infrastructure factors. A primary driver is the significantly larger patient population suffering from hematological malignancies and solid tumor across countries like China, India, and Japan, creating a vast unmet medical need that CAR T-cell therapies can address. Concurrently, substantial investments are being made by both governments and private entities to enhance healthcare infrastructure, including the establishment of advanced oncology centers and biotechnology hubs equipped to develop, manufacture, and administer these complex therapies. Rising disposable incomes in developing nations are gradually increasing patient access and affordability, while growing awareness among healthcare professionals and the general population about innovative cancer treatments is fueling demand.
Request Customized Report @ https://www.wissenresearch.com/ask-for-customization/
Contact us for free sample of car-t cell therapy market report: https://www.wissenresearch.com/contact/
Other Related Reports from Wissen Research
- Single-use Bioprocessing Market
- Cancer Biomarkers Market
- Laser Optics Market
- Biotherapeutics Market
- Smart Textile Market
About us
Wissen Research is a leading market research firm that serves over 800 clients, with 40% of the top 2,000 companies relying on us for insights into key business questions and the identification of new high-growth and niche revenue opportunities. We offer exclusive market intelligence from over 120 subject matter experts and analysts, complemented by our high-growth niche market studies and consulting services.
Our research methodology delivers quantifiable and actionable insights into interconnected market ecosystems shaped by disruptive technologies and emerging markets. We not only focus on factors that will impact our clients' revenue but also explore what could affect their customers' revenue by revealing latent and adjacent market opportunities.
We collaborate across all B2B sectors, engaging with C-level executives in areas such as R&D, intellectual property, strategy, marketing, sales, product development, and M&A.
Mayur Jain Wissen Research LLC Gould St, Ste R Sheridan, WY 82801 Phone: (+91) 7814300364 info@wissenresearch.com
